Journal article icon

Journal article

In silico analysis of the profilaggrin sequence indicates alterations in the stability, degradation route, and intracellular protein fate in filaggrin null mutation carriers

Abstract:
Background: Loss of function mutation in FLG is the major genetic risk factor for atopic dermatitis (AD) and other allergic manifestations. Presently, little is known about the cellular turnover and stability of profilaggrin, the protein encoded by FLG. Since ubiquitination directly regulates the cellular fate of numerous proteins, their degradation and trafficking, this process could influence the concentration of filaggrin in the skin. Objective: To determine the elements mediating the interaction of profilaggrin with the ubiquitin-proteasome system (i.e., degron motifs and ubiquitination sites), the features responsible for its stability, and the effect of nonsense and frameshift mutations on profilaggrin turnover. Methods: The effect of inhibition of proteasome and deubiquitinases on the level and modifications of profilaggrin and processed products was assessed by immunoblotting. Wild-type profilaggrin sequence and its mutated variants were analysed in silico using the DEGRONOPEDIA and Clustal Omega tool. Results: Inhibition of proteasome and deubiquitinases stabilizes profilaggrin and its high molecular weight of presumably ubiquitinated derivatives. In silico analysis of the sequence determined that profilaggrin contains 18 known degron motifs as well as multiple canonical and non-canonical ubiquitination-prone residues. FLG mutations generate products with increased stability scores, altered usage of the ubiquitination marks, and the frequent appearance of novel degrons, including those promoting C-terminus-mediated degradation routes. Conclusion: The proteasome is involved in the turnover of profilaggrin, which contains multiple degrons and ubiquitination-prone residues. FLG mutations alter those key elements, affecting the degradation routes and the mutated products' stability.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Authors

More by this author
Role:
Author
ORCID:
0000-0002-6229-0598
More by this author
Role:
Author
ORCID:
0000-0002-2991-3634
More by this author
Role:
Author
ORCID:
0000-0002-8957-5366
More by this author
Role:
Author
ORCID:
0000-0002-3232-5251
More by this author
Role:
Author
ORCID:
0000-0002-5110-4462


More from this funder
Funder identifier:
10.13039/100010269
Grant:
220875/Z/20/Z
More from this funder
Funder identifier:
10.13039/501100004281
Grant:
2021/41/N/NZ1/03473 2019/34/E/NZ6/00354 2021/42/E/NZ1/00190
More from this funder
Funder identifier:
10.13039/501100001870
Grant:
POIR.04.04.00-00-21FA/16-00


Publisher:
Frontiers Media
Journal:
Frontiers in Molecular Biosciences More from this journal
Volume:
10
Pages:
1105678-1105678
Article number:
1105678
Publication date:
2023-05-02
DOI:
EISSN:
2296-889X
ISSN:
2296-889X


Language:
English
Keywords:
Pubs id:
1859636
Local pid:
pubs:1859636
Source identifiers:
W4367853981
Deposit date:
2026-06-09
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP